<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105273</url>
  </required_header>
  <id_info>
    <org_study_id>AMCPHO-SCT0802</org_study_id>
    <nct_id>NCT01105273</nct_id>
  </id_info>
  <brief_title>Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia</brief_title>
  <official_title>HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may
      induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical
      allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may
      contribute to prevent developing severe acute graft versus host disease (GVHD) in
      haploidentical transplantation.

      Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine,
      cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical
      donors in treating patients with aplastic anemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the engraftment rate and survival of CD3±CD19 depleted haploidentical peripheral blood stem cell transplantation after conditioning with fludarabine, cyclophosphamide and anti-thymocyte globulin.</measure>
    <time_frame>2 years post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess engraftment and graft failure</measure>
    <time_frame>28 days post-transplant</time_frame>
    <description>Number of patients who failed to engraft by 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the risk of acute GVHD</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Number of patients with acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment related mortality</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Number of death after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival</measure>
    <time_frame>1 year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>HAPLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>On days -3 to -1</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Beginning on day 4 and continuing until blood counts recover</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/M2 once daily IV on days -6 to -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/kg IV on day-3 and -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD3±CD19 depleted hematopoietic stem cell transplantation</intervention_name>
    <description>Immunogenetic depletion on CliniMACS</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of life-threatening marrow failure (severe aplastic anemia) of nonmalignant
             etiology meeting 2 of the following criteria:

               -  Granulocyte count &lt; 500/mm3,

               -  Corrected reticulocyte count &lt; 1%,

               -  Platelet count &lt; 20,000/mm3

          -  No HLA-identical family member or closely matched (8 of 8 HLA-locus match) unrelated
             marrow donor available

          -  HLA-haploidentical related donor available

        Exclusion Criteria:

          -  Paroxysmal nocturnal hemoglobinuria or Fanconi anemia

          -  Clonal cytogenetic abnormalities or myelodysplastic syndromes

          -  Active fungal infections

          -  HIV positive

          -  Severe disease other than aplastic anemia that would severely limit the probability of
             survival during the graft procedure

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Joon Im, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/anemia.html</url>
    <description>Anemia</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=021679141&amp;QV1=FLUDARABINE</url>
    <description>Fludarabine</description>
  </link>
  <reference>
    <citation>Woodard P, Cunningham JM, Benaim E, Chen X, Hale G, Horwitz E, Houston J, Kasow K, Leung W, Wang W, Yusuf U, Handgretinger R. Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant. 2004 Feb;33(4):411-8.</citation>
    <PMID>14676782</PMID>
  </reference>
  <reference>
    <citation>Kremens B, Basu O, Grosse-Wilde H, Sauerwein W, Schaefer UW, Havers W. Transplantation of CD34-enriched peripheral stem cells from an HLA-haplotype mismatched donor to a patient with severe aplastic anemia. Bone Marrow Transplant. 2001 Jan;27(1):111-3.</citation>
    <PMID>11244448</PMID>
  </reference>
  <reference>
    <citation>Lacerda JF, Martins C, Carmo JA, Lourenço F, Juncal C, Ismail S, Lacerda JM. Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anemia. Biol Blood Marrow Transplant. 2005 May;11(5):399-400.</citation>
    <PMID>15846294</PMID>
  </reference>
  <reference>
    <citation>Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V; Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010 Apr 29;115(17):3437-46. doi: 10.1182/blood-2009-03-207001. Epub 2009 Dec 29.</citation>
    <PMID>20040760</PMID>
  </reference>
  <results_reference>
    <citation>Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol. 2012 Apr;157(1):139-42. doi: 10.1111/j.1365-2141.2011.08924.x. Epub 2011 Nov 5.</citation>
    <PMID>22055111</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>December 30, 2012</last_update_submitted>
  <last_update_submitted_qc>December 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Joon Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aplastic anemia</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>CD3±CD19 depletion</keyword>
  <keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

